<DOC>
	<DOCNO>NCT00214214</DOCNO>
	<brief_summary>The rationale study determine Campath-1H used patient recently diagnose type I DM , induce state immunological unresponsiveness subject safely preserve beta cell mass eliminate low insulin requirement , preserve excellent metabolic control .</brief_summary>
	<brief_title>A Pilot Study Determine Safety Campath-1H ( Anti-CD52 Antibody ) Therapy Newly Diagnosed Subjects With Type 1 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>Adult subject age 1835 , new onset type 1 diabetes mellitus ( within 212 week diagnosis ) , one islet autoantibody GAD , IA2 , IAA islet cell cytoplasmic antibody ( ICA ) within 2 week diabetes diagnosis . Subjects 18 year age 35 year age . Subjects previously receive organ transplant . Subjects currently receive systemic corticosteroid medical disease physician feel discontinuation corticosteroid contraindicate . Subjects history medical condition ( ) know affect blood glucose value ( i.e. , Cushing 's disease , acromegaly ) . Subjects history chronic systemic inflammatory autoimmune disease severe medical condition . ( A history treat hypothyroidism documentation normal serum thyroid hormone level exclusionary . ) Patients history hepatitis B , hepatitis C , HIV . PPD positive time evaluation . Thrombocytopenia neutropenia . Individuals consider thrombocytopenia platelet count &lt; 100,000 platelets/mm2 &lt; 3,000 WBC/ml . Subjects history renal , pulmonary , cardiac failure Subjects severe systemic infection . Only subject complete treatment show complete clinical resolution consider eligible study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>